Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda, Eisai, Chemiphar Ran Early Retirement Programs over Past Year: Survey
April 28, 2021
- Boehringer’s Japan Pharma Sales Rise 3.1% in 2020 on Ofev, Jardiance
April 28, 2021
- Daiichi Sankyo Sales Slip in FY2020 as Price Cuts, Deal Termination Weigh
April 28, 2021
- Xtandi Bullish, but Astellas Sales Wane 3.9% on Deal Wind-Ups; Profits Dip after Gene Therapy Trial Hold
April 28, 2021
- Daiichi Sankyo Gets Brazil, South Korea Rights to Esperion’s Hypercholesterolemia Drug
April 28, 2021
- AbbVie Files Maviret for Use in Children Age 3 Plus
April 28, 2021
- Nihon Generic Recalling Metformin Products over Carcinogen Risks
April 27, 2021
- SymBio’s Brincidofovir Gets FDA’s Fast-Track Status
April 27, 2021
- Kyorin Grabs Distribution Rights to MSD’s Cough Medicine in Japan
April 27, 2021
- Lilly, Daiichi Sankyo Roll Out Migraine Drug Emgality in Japan
April 27, 2021
- Novartis Offering Voluntary Redundancy for 3rd Consecutive Year, Targets Sales & Medical across Therapeutic Areas
April 27, 2021
- NanoCarrier, Axcelead Forge JV to Develop mRNA-Driven Articular Cartilage Drug
April 27, 2021
- Sota Yamaguchi to Assume New ASKA President Post in June
April 27, 2021
- Canada Starts Review of Medicago’s Rolling Submission for COVID-19 Vaccine
April 27, 2021
- Sumitomo Dainippon Ups FY2020 Guidance
April 26, 2021
- Lenvima/Keytruda Combo Filed for Uterine Body Cancer in Japan
April 26, 2021
- Gilead Seeks UC Indication for JAK Inhibitor Jyseleca in Japan
April 26, 2021
- Takeda’s ALK Inhibitor Alunbrig Now Available in Japan
April 26, 2021
- Santen to Launch New Plant in China, Commence Operations in 2025
April 26, 2021
- Delta-Fly/Nippon Chemiphar’s TME Therapy Now in Japan PII Trial
April 23, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…